31 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/31/3091406/0/en/Libtayo-cemiplimab-Phase-3-Data-in-the-Adjuvant-Treatment-of-Post-Surgical-High-Risk-Cutaneous-Squamous-Cell-Carcinoma-CSCC-Have-Potential-to-Be-Practice-Changing.html
30 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biolinerx-announces-new-pilot-phase-data-from-phase-2-combination-trial-of-motixafortide-in-first-line-pancreatic-cancer-pdac-to-be-presented-at-asco-2025-annual-meeting-302469367.html
28 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biohaven-presents-oncology-program-updates-and-preliminary-clinical-data-showcasing-innovative-trop2-and-fgfr3-antibody-drug-conjugates-adcs-incorporating-novel-topoix-payload-with-potential-to-treat-a-wide-variety-of-tumors-302466505.html
28 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250428550798/en/Ankyra-Therapeutics-Announces-Phase-1-Clinical-Data-at-the-2025-AACR-Annual-Meeting-and-the-first-patient-has-been-dosed-with-tolododekin-alfa-and-cemiplimab
05 Feb 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/regenerons-libtayo-reaches-blockbuster-status-and-has-potential-more-growth
04 Feb 2025
// BUSINESSWIRE